...
首页> 外文期刊>British Journal of Cancer >Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24|[plus]| prostate cancer patients
【24h】

Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24|[plus]| prostate cancer patients

机译:鉴定人组织相容性白细胞抗原-A24中具有免疫原性的甲状旁腺激素相关蛋白衍生肽前列腺癌患者

获取原文

摘要

Parathyroid hormone-related protein (PTHrP) is a key factor in the development of bone metastases, which are a major barrier in treating prostate cancer patients. In this study, we attempted to identify PTHrP-derived peptides immunogenic in human histocompatibility leukocyte antigen (HLA)-A24+ prostate cancer patients. Among four different PTHrP peptides carrying the HLA-A24 binding motif, both the PTHrP36–44 and PTHrP102–111 peptides efficiently induced peptide-specific cytotoxic T lymphocytes from peripheral blood mononuclear cells (PBMCs) of HLA-A24+ prostate cancer patients. Peptide-stimulated PBMCs showed cytotoxicity against prostate cancer cells in an HLA-A24-restricted manner. Experiments using antibodies and cold inhibition targets confirmed that their cytotoxicity was dependent on PTHrP peptide-specific and CD8+ T cells. Immunoglobulin G reactive to the PTHrP102–111 or PTHrP110–119 peptide was frequently detected in the plasma of prostate cancer patients, suggesting that the PTHrP102–111 peptide is able to elicit cellular and humoral immune responses in cancer patients. These results indicate that the PTHrP could be a promising target molecule for specific immunotherapy of HLA-A24+ prostate cancer patients with metastases.
机译:甲状旁腺激素相关蛋白(PTHrP)是骨转移发展的关键因素,而骨转移是治疗前列腺癌患者的主要障碍。在这项研究中,我们试图鉴定在人类组织相容性白细胞抗原(HLA)-A24 +前列腺癌患者中具有免疫原性的PTHrP衍生肽。在带有HLA-A24结合基序的四种不同的PTHrP肽中,PTHrP36-44和PTHrP102-111肽均能有效诱导HLA-A24 +前列腺癌患者外周血单个核细胞(PBMC)的肽特异性细胞毒性T淋巴细胞。肽刺激的PBMC以HLA-A24限制的方式显示出对前列腺癌细胞的细胞毒性。使用抗体和冷抑制靶标进行的实验证实,它们的细胞毒性取决于PTHrP肽特异性CD8 + T细胞。在前列腺癌患者的血浆中经常检测到对PTHrP102-111或PTHrP110-119肽具有反应性的免疫球蛋白G,这表明PTHrP102-111肽能够引起癌症患者的细胞和体液免疫反应。这些结果表明,PTHrP可能是针对HLA-A24 +转移性前列腺癌患者进行特异性免疫治疗的有希望的靶分子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号